9070
Yanxin Luo M.D. Ph.D The Sixth Affiliated Hospital of Sun Yat-sen University
Yanxin Luo M.D. Ph.D The Sixth Affiliated Hospital of Sun Yat-sen University Chief Physician, Doctoral Supervisor, Postdoctoral Supervisor Assistant to the Dean Director of Molecular Diagnostic Center, Department of Clinical Laboratory Medicine Dr. Yanxin Luo obtained his Bachelor's degree (2006) and Doctoral degree (2011) from Sun Yat-sen University School of Medicine, and completed his postdoctoral training in the United States from September 2009 to September 2013. With an international perspective, he has received systematic training both domestically and abroad, specializing in the molecular mechanisms of gastrointestinal tumor development and clinical translation. His clinical expertise lies in the detection, diagnosis and treatment of colorectal cancer, with a focus on scientific questions such as predicting colorectal cancer occurrence and mitigating recurrence and metastasis post-treatment. Dr. Luo has successively led five projects of the National Natural Science Foundation of China, the "Outstanding Youth" project of the Natural Science Foundation of Guangdong Province, and participated in the National Key Programs of China. He has authored over 80 SCI papers and holds nine authorized patents, and was the first to systematically elucidate a novel DNA methylation regulation mechanism in the malignant transformation of colorectal adenomas (Gastroenterology, 2014, Sole First and Co-corresponding Author). In the past 5 years, Dr. Luo has conducted in-depth research building upon the aforementioned foundation and made significant academic contributions, including (1) pioneering revelation that DNA methylation can control adenoma carcinogenesis and promote post-cancer cell progression through targeted regulation of actin and microtubules (Cancer Research, 2020, Sole Corresponding Author); (2) These key loci control the biological behaviors of tumors (Clinical Chemistry, 2019, Sole Corresponding Author), which provide important intervention targets for CRC treatment and prognosis (Journal of the National Cancer Institute, 2023, Last Corresponding Author); (3) Demonstrating that DNA methylation of non-tumor cells in the microenvironment can serve as cellular molecular tags for evaluating CRC immune response (Journal for Immunotherapy of Cancer, 2021, Last Corresponding Author), influence the biological behavior of the tumor (eBioMedicine, 2023, Last Corresponding Author), and also impact immunotherapy outcome (Journal for Immunotherapy of Cancer, 2022, Last Corresponding Author).
Binbin Liu M.D. PhD The Sixth Affiliated Hospital of Sun Yat-sen University
Research More >
We focuses on the development of colorectal cancer, conducting research in the fields of tumor epigenetics, clinical proteomics, and translational medicine. We have undertaken 10 projects funded by the National Natural Science Foundation, 6 projects funded by provincial and ministerial-level research funds, and the Guangdong Provincial Outstanding Youth Program Grant. We have also participated in National Basic Research Program, and National Key Research and Development Program of China.